Palvella Therapeutics, Inc. (PVLA) EPS (Basic) (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed EPS (Basic) for 12 consecutive years, with $0.12 as the latest value for Q4 2024.
- On a quarterly basis, EPS (Basic) fell 99.42% to $0.12 in Q4 2024 year-over-year; TTM through Dec 2024 was -$6.37, a 200.95% decrease, with the full-year FY2024 number at -$7.83, down 457.53% from a year prior.
- EPS (Basic) was $0.12 for Q4 2024 at Palvella Therapeutics, up from -$2.19 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of $20.52 in Q4 2023 to a low of -$14.15 in Q1 2023.
- A 5-year average of -$0.09 and a median of -$0.13 in 2021 define the central range for EPS (Basic).
- Biggest YoY gain for EPS (Basic) was 18754.55% in 2023; the steepest drop was 20114.29% in 2023.
- Palvella Therapeutics' EPS (Basic) stood at -$0.26 in 2020, then surged by 50.0% to -$0.13 in 2021, then increased by 15.38% to -$0.11 in 2022, then skyrocketed by 18754.55% to $20.52 in 2023, then crashed by 99.42% to $0.12 in 2024.
- Per Business Quant, the three most recent readings for PVLA's EPS (Basic) are $0.12 (Q4 2024), -$2.19 (Q3 2024), and -$2.76 (Q2 2024).